Avalo Therapeutics Inc
$ 17.58
-4.25%
05 Mar - close price
- Market Cap 339,894,000 USD
- Current Price $ 17.58
- High / Low $ 18.52 / 17.37
- Stock P/E N/A
- Book Value 5.13
- EPS -13.42
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -1.75 %
- 52 Week High 20.72
- 52 Week Low 3.39
About
Avalo Therapeutics Inc is a clinical-stage biotechnology firm dedicated to the development of groundbreaking therapies for rare and underserved conditions, with a particular emphasis on immunological regulation. The company boasts a strong pipeline of proprietary therapeutic candidates aimed at addressing serious diseases with substantial unmet medical needs. Avalo's unwavering commitment to scientific innovation and patient-centric solutions allows it to navigate the complex biopharmaceutical landscape effectively. By harnessing its expertise in disease mechanisms, Avalo aims to achieve successful clinical trial outcomes and deliver transformative therapies to patients in need.
Analyst Target Price
$36.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-27 | 2024-11-07 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-09 | 2023-08-03 | 2023-05-04 | 2023-03-29 |
| Reported EPS | -2.19 | -1.92 | -1.2867 | -2.74 | -1.25 | -14.07 | -141 | -116.21 | -0.11 | -0.59 | -0.85 | -1.04 |
| Estimated EPS | -1.22 | -1.19 | -1.605 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -1.1 | -0.8 | -0.97 | -0.73 |
| Surprise | -0.97 | -0.73 | 0.3183 | -4.405 | -0.06 | -7.37 | -139.82 | -111.41 | 0.99 | 0.21 | 0.12 | -0.31 |
| Surprise Percentage | -79.5082% | -61.3445% | 19.8318% | -264.5646% | -5.042% | -110% | -11849.1525% | -2321.0417% | 90% | 26.25% | 12.3711% | -42.4658% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.54 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2026-03-03 13:52:29
Avalo Therapeutics (AVTX) Chief Strategy Officer Jennifer Riley has been granted stock options to purchase 95,000 shares of common stock at a reported price of $0.00 per share. These compensatory options will begin vesting 25% on February 26, 2027, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on her continued employment. This transaction is an acquisition of derivative equity holdings, not a sale of existing shares.
2026-03-03 13:52:29
Avalo Therapeutics' CFO, Christopher Ryan Sullivan, was granted 105,000 stock options on February 26, 2026, as part of his equity compensation. These options will vest 25% on February 26, 2027, with the remainder vesting monthly over the subsequent three years, contingent on his continued service. This grant aligns the CFO's incentives with the company's long-term performance.
2026-03-02 21:51:22
Avalo Therapeutics (AVTX) reported through an SEC Form 4 filing that its Chief Legal Officer, Paul Varki, was granted 80,000 stock options on February 26, 2026. These options have an exercise price of $0.00, indicating a compensatory award. The vesting schedule dictates that 25% will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent three years, contingent on Varki's continued employment.
2026-03-02 21:51:22
Avalo Therapeutics' Chief Business Officer, Boyd Taylor, was awarded 95,000 stock options according to a recent Form 4 SEC filing. These derivative securities are subject to a vesting schedule, with 25% vesting on February 26, 2027, and the remainder in equal monthly installments over the subsequent three years, contingent on his continued service. The transaction is identified as a compensation-related grant, held directly by Taylor with an exercise price of $17.64.
2026-03-02 21:51:22
Avalo Therapeutics, Inc. (AVTX) Chief Medical Officer Mittie Doyle was granted 105,000 stock options on February 26, 2026, with an exercise price of $0.0000 per share. The options vest 25% on February 26, 2027, with the remainder vesting monthly over the following three years, contingent on continued employment. This insider transaction was disclosed in a Form 4 SEC filing.
2026-03-02 20:51:22
Avalo Therapeutics (AVTX) CEO Neil Garry Arthur was granted 286,000 stock options on February 26, 2026. These options will vest 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent three years, contingent on his continued service. This transaction was reported in an SEC Form 4 filing, indicating an acquisition of derivative securities rather than a direct stock purchase or sale.
